Locoregional recurrence in patients with triple-negative breast cancer: Preliminary results of a single institution study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 231-237

  Dragun, Anthony E ^a   Pan, Jianmin ^b   Rai, Shesh N ^b   Kruse, Barbara ^c   Jain, Dharamvir ^c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; local control; triple negative

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LYMPH NODE; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER;

ACTUARIAL ANALYSIS; ADULT; AGED; BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KENTUCKY; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79958254309     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181dea993     Document Type: Article

References (15)

1. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27-44. (Pubitemid 352009225)
2. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568-2581.
3. Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol). 2008;20:40-45.
4. Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol. 2007; 20:864-870. (Pubitemid 47077270)
5. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4.
6. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11: 5678-5685. (Pubitemid 41170290)
7. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652-5657. (Pubitemid 46631305)
8. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373-2378.
9. Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419-1426.
10. Krasin MJ, Rai SN, Kun LE, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy. J Clin Oncol. 2005;23:8406-8413.
11. Meidler J, Abdul-Karim F, Wang N, Baar J. MUC1 expression in early-stage triple-negative breast cancer. Paper presented at: 32nd Annual San Antonio Breast Cancer Symposium; 2009; San Antonio, TX.
12. Zhou P, Recht A. Young age and outcome for women with early-stage invasive breast carcinoma. Cancer. 2004;101:1264-1274. (Pubitemid 39180381)
13. Chargari C, Toillon RA, Macdermed D, et al. Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncol. 2009;10:53-60.
14. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004;64:64-71. (Pubitemid 38114083)
15. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18:574-583. (Pubitemid 30078538)